Fluticasone

From Wikipedia, the free encyclopedia

Fluticasone
Systematic (IUPAC) name
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-
6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
6,7,8,11,12,14,15,16-octahydrocyclopenta[a]
phenanthrene-17-carbothioate
Identifiers
CAS number 80474-14-2
ATC code D07AC17 & D07AC04 (topical)
PubChem 5311101
DrugBank APRD00065
Chemical data
Formula C22H27F3O4S 
Mol. mass 444.508 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 0.51% (Intranasal)
Protein binding 91%
Metabolism Intranasal
Hepatic (CYP3A4-mediated)
Half life 10 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C for Intranasal and Inhaled
Legal status

POM(UK) ℞-only(US)
Routes Intranasal, Inhaled, Topical Cream or Ointment

Fluticasone is a potent synthetic corticosteroid often prescribed as treatment for asthma and allergic rhinitis.

The related fluticasone propionate is marketed with the brand names Flixotide (UK) for asthma and Flixonase (UK) for allergic rhinitis by Allen & Hanburys. In the US, it is marketed for asthma as Flovent, and allergic rhinitis as Flonase, by GlaxoSmithKline. GlaxoSmithKline also markets a combination of fluticasone and salmeterol as Advair (US) or Seretide (UK).

The related fluticasone furoate is marketed by GlaxoSmithKline as Veramyst (US) for the treatment of allergic rhinitis.

It is also used as a cream or ointment for the treatment of eczema and psoriasis (Cutivate US & UK).

Contents

[edit] Mechanism of action

Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediate production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma. Typically, however, the action on the cells affected requires several days. Therefore, inhaled steroids are not used for immediate relief of asthma, but instead as preventive and maintenance therapy.

[edit] Nasal spray

[edit] Dosage

  • Adults: The recommended dosage for adults is 100 micrograms (two sprays in each nostril) once daily. This may be increased to maximum of twice daily use if required. When control is achieved dose is reduced to 50 micrograms (one spray) daily.
A canister of Flovent in the inhaler.
A canister of Flovent in the inhaler.
  • Adolescents and children: The recommended dosage for children (4 years of age or older in US, but only from 12 years in UK) is 50 micrograms (one spray) into each nostril once daily. This may be increased to maximum of twice daily use if required.

[edit] Flonase patent issues

GlaxoSmithKline's patent on Flonase expired in May 2004. The Food and Drug Administration (FDA) approved the sale of a generic version of Flonase on February 22, 2006. On February 23, 2006, GlaxoSmithKline (GSK) was able to obtain a temporary 10-day restraining order from a federal judge in Baltimore blocking the shipment and sales of the approved generic versions of Flonase. The restraining order lasted until March 6, 2006. The basis of the complaint by GSK was that the FDA failed to follow its own regulations in approving the generics and failed to apply the same quality standards for the generic version as it did for Flonase. GSK made these arguments in petitions filed with the FDA, but the FDA rejected those petitions. The Maryland District Court denied the request by GSK to extend the ban on Flonase generics beyond March 6, 2006, and GSK released a statement that they would not appeal the ruling.[1] The ruling meant that sales of generic versions of Flonase could proceed.

[edit] References

[edit] Clinical trials

This listing is NOT complete and should NOT be construed as support for treatment decisions. See also PubMed clinical manuscripts referring to fluticasone

both support a positive outcome for use of fluticasone in patients with chronic obstructive pulmonary disease, also referred to as COPD

[edit] External links

v • d • e
Decongestants and other nasal preparations (R01)
Topical: sympathomimetics, plain
Topical: antiallergic agents, excluding corticosteroids
Topical: corticosteroids
Topical: other nasal preparations
Systemic use: Sympathomimetics
v • d • e
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Glucocorticoids
Beclometasone • Budesonide • Ciclesonide • Fluticasone • Mometasone
Anticholinergics
Mast cell stabilizers
Xanthines
Leukotriene antagonists
Lipoxygenase inhibitor
Combination products
v • d • e
Corticosteroids - glucocorticoid/receptor and mineralocorticoid/receptor
(A07EA, C05AA, D07, D10AA, H02, R01AD, R03BA, S01BA, S02B, and S03B)
Endogenous
Others
Alclometasone, Amcinonide, Beclometasone, Betamethasone, Budesonide, Ciclesonide, Clobetasol, Clobetasone, Clocortolone, Cloprednol, Cortivazol, Deflazacort, Deoxycorticosterone, Desonide, Desoximetasone, Dexamethasone, Diflorasone, Diflucortolone, Difluprednate, Fluclorolone, Fludrocortisone, Fludroxycortide, Flumetasone, Flunisolide, Fluocinolone acetonide, Fluocinonide, Fluocortin, Fluocortolone, Fluorometholone, Fluperolone, Fluprednidene, Fluticasone, Formocortal, Halcinonide, Halometasone, Hydrocortisone aceponate, Hydrocortisone buteprate, Hydrocortisone butyrate, Loteprednol, Medrysone, Meprednisone, Methylprednisolone,Methylprednisolone aceponate, Mometasone furoate, Paramethasone, Prednicarbate, Prednisone, Prednisolone, Prednylidene, Rimexolone, Tixocortol, Triamcinolone, Ulobetasol